Sugi Predict

Sugi Predict / Compounds / SCHEMBL2553988

SCHEMBL2553988

SCHEMBL2553988

COc1cc(/C=C/C(=O)O)ccc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.69
▸ ALDH1A1 P00352 3/20 0.69
▸ HPGD P15428 2/20 0.69
▸ HSD17B10 Q99714 2/20 0.69
▸ ALOX15 P16050 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ SNCA P37840 2/20 0.58
▸ PKM P14618 2/20 0.58
▸ CA12 O43570 1/20 0.58
▸ CA1 P00915 1/20 0.58
▸ CA2 P00918 1/20 0.58
▸ CA3 P07451 1/20 0.58
▸ CSNK2A2 P19784 1/20 0.58
▸ CA4 P22748 1/20 0.58
▸ CA6 P23280 1/20 0.58
▸ CA5A P35218 1/20 0.58
▸ CA7 P43166 1/20 0.58
▸ CSNK2B P67870 1/20 0.58
▸ CSNK2A1 P68400 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656553 1.00 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL2553992 1.00 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL2408521 0.93 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL2408525 0.93 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL23805172 0.91 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL14342653 0.90 FDPS (0.61) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL9553571 0.90 FDPS (0.61) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL17529412 0.88 KMT2A (0.56) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL22770082 0.88 KDM4E (0.57) KDM4EALDH1A1HPGDHSD17B10ALOX15
SCHEMBL23665036 0.87 KMT2A (0.54) KDM4EALDH1A1HPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111440068-A Cinnamate derivatives and their use as tyrosinase inhibitors and gels 陕西中医药大学 2020-07-24 — — CN claimed
EP-3674289-B9 LONG-ACTING RASAGILINE PRODRUG, PREPARATION METHOD AND USE THEREOF GUANGZHOU HENOVCOM BIOSCIENCE CO LTD (CN) 2023-12-13 — — EP disclosed
CN-116903465-A Ferulic acid modified butylphthalide ring-opening derivative and preparation method and application thereof 重庆医科大学附属大学城医院 2023-10-20 — — CN disclosed
EP-3674289-B1 LONG-ACTING RASAGILINE PRODRUG, PREPARATION METHOD AND USE THEREOF GUANGZHOU HENOVCOM BIOSCIENCE CO LTD (CN) 2023-10-11 — — EP disclosed
CN-111440068-B Cinnamate derivative and application thereof as tyrosinase inhibitor and gel 陕西中医药大学 2023-08-11 — — CN disclosed
US-11578092-B2 Compound for preventing or treating neurodegenerative disease and application thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2023-02-14 — — US disclosed
US-11369583-B2 Long-acting prodrugs of rasagiline, preparing methods and uses thereof GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD (CN) 2022-06-28 — — US disclosed
EP-2925755-B1 NEUROPROTECTIVE AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV WAYNE STATE (US) 2021-09-08 — — EP disclosed
WO-2021143812-A1 METHOD FOR PREPARING N-(β-L-RHAMNOPYRANOSYL)FERULAMIDE AND USE THEREOF 上海医药集团股份有限公司 2021-07-22 — — WO disclosed
US-20210040132-A1 NOVEL COMPOUND FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2021-02-11 — — US disclosed
US-20190038622-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES WAYNE STATE UNIVERSITY 2019-02-07 — — US disclosed
US-10125127-B2 Neuroprotective agents for treatment of neurodegenerative diseases WAYNE STATE UNIVERSITY (US) 2018-11-13 — — US disclosed
US-20180105492-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (ES) 2018-04-19 — — US disclosed
US-20180105492-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (ES) 2018-04-19 — — US disclosed
EP-3208262-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINO-1H-INDOLE ACRYLATE, AND THE USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Fundación Para La Investigación Biomédica Del Hospital De La Princesa (ES) 2017-08-23 — — EP disclosed
US-20150299180-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES WAYNE STATE UNIVERSITY (US) 2015-10-22 — — US disclosed
US-8637674-B2 Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2014-01-28 — — US disclosed
EP-2556062-A1 AMIDE DERIVATIVES OF CINNAMIC, FERULIC AND AVENALUMIC SERIES, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME Produits Chimiques Auxiliaires et de Synthese (FR) 2013-02-13 — — EP disclosed
US-20120232117-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2012-09-13 — — US disclosed
WO-2011124844-A1 AMIDE DERIVATIVES OF CINNAMIC, FERULIC AND AVENALUMIC SERIES, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) 2011-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299180-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES RTN4, NR4A1, NR4A3 KDM4E 1641/4885ALDH1A1 1123/4885HPGD 1787/4885
US-11369583-B2 Long-acting prodrugs of rasagiline, preparing methods and uses thereof PARK7, RAB7A, SNCA KDM4E 3909/4885ALDH1A1 1902/4885HPGD 993/4885
US-11578092-B2 Compound for preventing or treating neurodegenerative disease and application thereof NGF, CHAT, GAP43 KDM4E 3017/4885ALDH1A1 832/4885HPGD 496/4885
US-20210040132-A1 NOVEL COMPOUND FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF NGF, CHAT, GAP43 KDM4E 2914/4885ALDH1A1 1019/4885HPGD 725/4885
US-20190038622-A1 NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES SMN1; SMN2, PARK7, SNCA KDM4E 3307/4885ALDH1A1 1481/4885HPGD 1216/4885
US-20180105492-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES NFE2L2, KEAP1, HTT KDM4E 3338/4885ALDH1A1 606/4885HPGD 956/4885
US-10125127-B2 Neuroprotective agents for treatment of neurodegenerative diseases RTN4, NR4A1, NR4A3 KDM4E 1641/4885ALDH1A1 1123/4885HPGD 1787/4885
US-20120232117-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME PTH1R, VDR, SOST KDM4E 1561/4885ALDH1A1 2869/4885HPGD 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.